论文部分内容阅读
目的观察对比羟考酮控释片与吗啡缓释片治疗中重度癌痛临床疗效。方法选取78例中重度癌痛患者作为实验对象,随机将其均分成两组,就吗啡缓释片治疗(对照组,n=39)与羟考酮控释片治疗(观察组,n=39)的临床疗效展开探讨。结果从治疗总有效率方面分析,观察组和对照组的治疗总有效率为79.48%、61.54%,组间差异显著,P<0.05,差异有统计学意义。且观察组部分缓解明显高于对照组,P<0.05;从不良反应发生情况对比,观察组患者的便秘、呕吐、嗜睡的发生率分别为为25.64%、25.64%、20.51%,对照组的便秘、呕吐、嗜睡的发生率分别为分56.41%,33.33%,30.77%,组间差异均比较大,实验差异经χ2检验,P<0.05,在其他不良反应发生情况方面差异无统计学意义,P>0.05。结论相比而言,采用羟考酮控释片治疗中重度癌痛的疗效更显著,在临床上更有普及的价值。
Objective To compare the clinical efficacy of oxycodone controlled-release tablets and morphine sustained-release tablets in the treatment of moderate-severe cancer pain. Methods Totally 78 patients with moderate-to-severe cancer pain were selected and randomly divided into two groups. The treatment group was treated with morphine sustained release tablets (n = 39) and oxycodone controlled release tablets (n = 39) ) Clinical efficacy to explore. Results From the analysis of the total effective rate of treatment, the total effective rate of observation group and control group was 79.48% and 61.54%, the difference between the two groups was significant (P <0.05). The difference was statistically significant. And the partial remission in the observation group was significantly higher than that in the control group, P <0.05; compared with the incidence of adverse reactions, the incidence of constipation, vomiting and drowsiness in the observation group were 25.64%, 25.64% and 20.51% , Vomiting and lethargy were 56.41%, 33.33% and 30.77% respectively. There were significant differences among groups. The difference of test was significant by χ2 test, P <0.05. There was no significant difference in the occurrence of other adverse reactions, P > 0.05. Conclusion In contrast, the use of oxycodone controlled release tablets in the treatment of moderate-to-severe cancer pain is more significant, clinically more universal value.